Structure-Guided Antiviral Design: Computational Modeling of Spike Protein Dynamics in Emerging Coronaviruses

Introduction

Emerging coronaviruses represent a persistent threat to animal and public health due to their zoonotic potential and capacity for rapid evolution. The spike (S) protein, a class I viral fusion protein, mediates host cell entry by binding to cellular receptors and catalyzing membrane fusion [1]. Its dynamic conformational landscape, which includes pre-fusion, intermediate, and post-fusion states, is a central target for antiviral intervention [1, 2]. Structure-guided antiviral design leverages atomic-level models of the spike protein to identify conserved structural motifs, cryptic binding pockets, and epitopes that are less susceptible to mutational escape [3, 4, 5]. Computational methods such as molecular dynamics (MD) simulations, free energy calculations, and protein-ligand docking have become indispensable tools for characterizing spike protein dynamics and for rationally designing inhibitors that block viral entry or replication [6, 7, 8].

This article provides a technical overview of the computational structural biology techniques used to model coronavirus spike protein dynamics, with a focus on emerging coronaviruses relevant to veterinary medicine. It discusses how these methods are applied to identify conserved epitopes and cryptic binding sites, and how they inform the design of broad-spectrum antivirals and vaccine updates. The discussion is grounded in the context of animal coronaviruses, including bat-derived strains, and draws parallels to well-studied systems such as SARS-CoV-2 where comparative host-range parallels exist [3, 4, 5].

Computational Structural Biology Techniques for Spike Protein Modeling

Molecular Dynamics Simulations

Molecular dynamics simulations provide a time-resolved view of spike protein conformational changes at atomic resolution [6, 7, 8]. By solving Newton's equations of motion for a system of atoms, MD simulations capture the thermal fluctuations and large-scale rearrangements that underlie receptor binding and membrane fusion [9]. For coronavirus spike proteins, all-atom MD simulations have been used to study the opening of the receptor-binding domain (RBD), the stability of the pre-fusion trimer, and the transition to the post-fusion six-helix bundle [1, 2, 10].

Simulations are typically performed using explicit solvent models and physiological ionic strength, with the protein embedded in a lipid bilayer when studying membrane-anchored regions [6, 7]. The choice of force field (e.g., CHARMM, AMBER, OPLS) critically affects the accuracy of the dynamics [6, 7]. Enhanced sampling techniques, such as replica exchange MD and metadynamics, are employed to overcome energy barriers and explore rare conformational events [9]. For example, triplicate MD simulations have been used to evaluate the stability of mutant peptide inhibitors bound to the SARS-CoV-2 main protease, demonstrating the utility of MD in assessing binding mode persistence [6].

Free Energy Calculations

Free energy calculations quantify the thermodynamic driving forces for ligand binding and conformational transitions [7, 11, 12]. Methods such as free energy perturbation (FEP), thermodynamic integration, and MM-GBSA (molecular mechanics generalized Born surface area) are routinely applied to rank candidate inhibitors and to predict the impact of mutations on binding affinity [7, 11, 12, 13]. FEP simulations, in particular, have been used to guide the optimization of non-covalent inhibitors of the SARS-CoV-2 main protease by accurately predicting relative binding free energies [11, 12]. In the context of spike protein dynamics, free energy landscapes constructed from MD trajectories reveal the relative populations of different conformational states and the barriers between them [13, 9].

Protein-Ligand Docking

Molecular docking algorithms predict the preferred orientation of a small molecule or peptide when bound to a protein target [8, 14, 15]. Docking is used to screen virtual libraries of compounds against the spike protein or its isolated domains, such as the RBD or the heptad repeat regions [1, 8, 16]. Structure-guided docking, informed by co-crystal structures or cryo-EM maps, improves the accuracy of predicted binding modes [4, 17, 18]. For example, docking simulations have been employed to design peptide nucleic acid (PNA) antisense oligomers targeting the RNA-dependent RNA polymerase, as well as to identify cannabinoid-inspired inhibitors of the 2'-O-methyltransferase [8, 19, 20]. Docking studies also help rationalize structure-activity relationships (SAR) by revealing key hydrogen bonds and hydrophobic contacts [14, 15].

Protein Structure Prediction: AlphaFold2 and ESMFold

Accurate three-dimensional models of spike proteins are essential when experimental structures are unavailable. Deep learning-based methods such as AlphaFold2 and ESMFold have revolutionized protein structure prediction by achieving near-experimental accuracy for many targets [2, 10]. These tools have been applied to model the spike proteins of novel bat coronaviruses, enabling rapid assessment of receptor binding interfaces and potential zoonotic risk [2, 10]. AlphaFold2 predictions can be used as starting points for MD simulations and docking studies, although careful validation against experimental data (e.g., cryo-EM maps) is recommended [2, 10]. The integration of predicted structures with molecular dynamics has been demonstrated in the design of self-assembling trivalent nanobody clusters targeting the SARS-CoV-2 spike protein [2, 10].

Membrane-Embedded Simulation Tools

Coronavirus spike proteins are anchored in the viral membrane via a transmembrane domain, and their function is modulated by the lipid environment. Membrane-embedded simulations using tools such as CHARMM-GUI or GROMACS with lipid bilayer models provide a more realistic context for studying spike dynamics [6, 7]. These simulations capture the influence of membrane composition on spike conformational stability and the exposure of fusion peptides [1, 6]. Coarse-grained MD models, which reduce computational cost by grouping atoms into beads, are particularly useful for studying large-scale rearrangements of the trimeric spike over microsecond timescales [6, 7].

Conserved Epitopes and Cryptic Binding Sites

A major goal of structure-guided antiviral design is the identification of conserved regions on the spike protein that are essential for function and therefore less likely to mutate without fitness cost [1, 4, 5]. The heptad repeat (HR) regions HR1 and HR2, which form the six-helix bundle during membrane fusion, are highly conserved across coronaviruses [1, 9]. Peptide inhibitors that mimic HR2 and competitively block six-helix bundle formation have been developed and optimized using computational design [1, 9]. For example, the EK1 peptide, a pan-coronavirus fusion inhibitor, was refined through structure-guided computational optimization to enhance its inhibitory potency against multiple coronaviruses [9].

Cryptic binding sites are pockets that are not apparent in static crystal structures but become transiently accessible during protein dynamics [3, 21, 22]. MD simulations can reveal these transient pockets, which may serve as targets for small-molecule inhibitors. A notable example is the Val70Ub site on the SARS-CoV-2 papain-like protease (PLpro), a cryptic pocket that was discovered through co-crystal structures and exploited for inhibitor design [3, 21, 22]. Inhibitors targeting this site, such as Jun12682 and MR1-114, have shown potent antiviral activity in animal models [3, 21, 22]. Similarly, the BL2 groove pocket on PLpro has been targeted by non-covalent inhibitors with nanomolar potency [3, 5, 22].

The spike protein itself contains cryptic epitopes that are exposed only in specific conformational states. For instance, the "3-RBD-up" conformation of the SARS-CoV-2 spike exposes epitopes that are occluded in the "3-RBD-down" state [2, 10]. Structure-guided design of trivalent nanobody clusters has exploited this conformational plasticity to lock the spike in a non-infectious state [2, 10]. Cryo-EM structures of these complexes confirm that the designed binders engage all three RBDs simultaneously, providing a synergistic neutralization mechanism [2, 10].

Implications for Broad-Spectrum Antiviral Design and Vaccine Updates

The insights gained from computational modeling of spike protein dynamics directly inform the development of broad-spectrum antivirals and vaccine updates. Broad-spectrum inhibitors target conserved structural elements, such as the fusion peptide or the S2 stem helix, that are shared across coronavirus genera [1, 18, 9]. Structure-guided optimization of peptide inhibitors has led to candidates with activity against multiple coronaviruses, including those from bats and other animal reservoirs [1, 9]. For example, inhibitors incorporating a 1,3,2-oxazaphospholidin-3-one scaffold have shown potent activity against both SARS-CoV-2 and MERS-CoV 3CLpro, demonstrating cross-genus efficacy [18].

Vaccine updates rely on the identification of epitopes that are both conserved and immunogenic. Computational mapping of antibody-epitope interfaces, combined with deep mutational scanning, can predict which spike mutations are likely to escape neutralizing antibodies [2, 10]. Structure-guided design of immunogens that present conserved epitopes in a stable conformation can elicit broader and more durable immune responses [2, 10]. For veterinary applications, such approaches are critical for developing vaccines against emerging coronaviruses in livestock and companion animals, where rapid adaptation of the virus may outpace traditional vaccine development.

The workflow for structure-guided antiviral design typically proceeds through iterative cycles of computational prediction, experimental validation, and optimization, as illustrated in Figure 1.

flowchart TD
    A[Target Selection: Spike Protein or Protease], > B[Structure Acquisition: X-ray, Cryo-EM, or AlphaFold2]
    B, > C[Computational Modeling: MD Simulations, Docking, FEP]
    C, > D[Identification of Conserved Epitopes / Cryptic Pockets]
    D, > E[Design of Inhibitors or Immunogens]
    E, > F[In Vitro / In Vivo Validation]
    F, > G{Activity Acceptable?}
    G, >|Yes| H[Lead Optimization and ADME Profiling]
    G, >|No| C
    H, > I[Preclinical Testing in Animal Models]
    I, > J[Clinical / Field Trials]

Figure 1. Workflow for structure-guided antiviral design targeting coronavirus spike proteins and associated proteases.

Conclusion

Structure-guided antiviral design, powered by computational modeling of spike protein dynamics, has emerged as a powerful paradigm for combating emerging coronaviruses. Molecular dynamics simulations, free energy calculations, docking, and deep learning-based structure prediction enable the identification of conserved epitopes and cryptic binding sites that are otherwise inaccessible. These computational approaches have led to the discovery of potent inhibitors targeting viral proteases and fusion machinery, with demonstrated efficacy in animal models [3, 4, 5, 21, 22]. For veterinary medicine, the ability to rapidly model spike proteins from novel animal coronaviruses and to design broad-spectrum interventions is essential for pandemic preparedness. Continued integration of computational and experimental methods will accelerate the development of antivirals and vaccines that can keep pace with viral evolution.

References

[1] Gonepudi, N. K., Awuah, H. B., Xu, W., et al. Structure-Guided Design of Peptide Inhibitors Targeting Class I Viral Fusion Proteins. Pathogens, 2025. Link

[2] Jiang, X., Qin, Q., Zhu, H., et al. Structure-guided design of a trivalent nanobody cluster targeting SARS-CoV-2 spike protein. International Journal of Biological Macromolecules, 2023. Link

[3] Ansari, A., Ruiz, F., Tan, B., et al. Structure-guided design of SARS-CoV-2 PLpro inhibitors with in vivo antiviral efficacy. Structural Dynamics, 2025. Link

[4] Dampalla, C. S., Kim, Y., Zabiegala, A., et al. Structure-Guided Design of Potent Coronavirus Inhibitors with a 2-Pyrrolidone Scaffold: Biochemical, Crystallographic, and Virological Studies. Journal of Medicinal Chemistry, 2024. Link

[5] Sharafi, M., Teh, W. P., Green, J., et al. Structure-Guided Design of Potent and Selective Covalent Inhibitors Targeting the SARS-CoV-2 Papain-like Protease. Journal of Medicinal Chemistry, 2026. Link

[6] Bhagat, A., Kelam, L. M., Samanta, N., et al. Structure-guided design and triplicate molecular dynamics evaluation of mutant peptide inhibitors targeting SARS-CoV-2 main protease (Mpro). In Silico Pharmacology, 2025. Link

[7] Kang, K. M., Jang, Y., Lee, S. S., et al. Discovery of antiviral SARS-CoV-2 main protease inhibitors by structure-guided hit-to-lead optimization of carmofur. European Journal of Medicinal Chemistry, 2023. Link

[8] Shehzadi, K., Yu, M.-J., Liang, J. De Novo Potent Peptide Nucleic Acid Antisense Oligomer Inhibitors Targeting SARS-CoV-2 RNA-Dependent RNA Polymerase via Structure-Guided Drug Design. International Journal of Molecular Sciences, 2023. Link

[9] Gao, P., Liu, S., Chi, X., et al. Computational optimization of a pan-coronavirus fusion inhibitory peptide targeting spike’s heptapeptide repeat region. Biosafety and Health, 2025. Link

[10] Qin, Q., Jiang, X., Huo, L., et al. Computational design and engineering of self-assembling multivalent microproteins with therapeutic potential against SARS-CoV-2. Journal of Nanobiotechnology, 2024. Link

[11] Carney, D. W., Leffler, A. E., Bell, J. A., et al. Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity. Bioorganic & Medicinal Chemistry, 2024. Link

[12] Okabe, A., Carney, D. W., Tawada, M., et al. Discovery of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 Main Protease through Computer-Aided Drug Design. Journal of Medicinal Chemistry, 2025. Link

[13] Bashir, F., Bashir, A., Ganai, S. A., et al. Drug Designing and Molecular Dynamics Identifies Cyanobacterial Nodularin-R as the Candidate Molecule Against SARS-CoV-2 Main Protease (Mpro). Journal of Environmental Science and Agricultural Research, 2025. Link

[14] Al-Joufi, F., Alwabsi, H. A., Mojally, M., et al. In-Silico Guided Design, Synthesis and Structure Activity Relationship Studies of Quinoline Based Scaffolds as Novel SARS-CoV2- Main Protease Inhibitors: Insights into Experimental and Computational Profiling. Journal of Computational Biophysics and Chemistry, 2026. Link

[15] Alwethaynani, M. S., Alzhrani, K., Sarfraz, H., et al. Structure activity relationship-guided scaffold hopping for identification of novel thiadiazole derivatives as potent SARS-CoV-2 Mpro inhibitors. Zeitschrift für Naturforschung C, 2026. Link

[16] Zannella, C., Fernández, F. R., Santoro, F., et al. Structure-Guided Design of Temporin-Derived Peptides Reveals Potent Dual-Mechanism Inhibitors of SARS-CoV-2. Journal of Medicinal Chemistry, 2026. Link

[17] Deshmukh, M., Ippolito, J., Zhang, C.-H., et al. Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease. Structure, 2021. Link

[18] Nguyen, H. N., Ranasinghe, P. S., Ilesinghe, I. S. G., et al. Structure-guided design of broad-spectrum inhibitors of coronaviral proteases embodying a 1,3,2-oxazaphospholidin-3-one scaffold as a versatile design element. European Journal of Medicinal Chemistry, 2026. Link

[19] Shehzadi, K., Kalsoom, I., Yu, M.-J., et al. Design and in-silico evaluation of PNA-based novel pronucleotide analogues targeting RNA-dependent RNA polymerase to combat COVID-19. Journal of Biomolecular Structure and Dynamics, 2025. Link

[20] Benjamin, M. M., Hanna, G. S., Dickinson, C. F., et al. Cannabinoid-Inspired Inhibitors of the SARS-CoV-2 Coronavirus 2′-O-Methyltransferase (2′-O-MTase) Non-Structural Protein (Nsp10-16). Molecules, 2024. [Link](https://www.semanticscholar.org/paper/e75647397ae9ad01913d501048985d

[21] Gannarapu, M. R., Indukuri, D., Holberg, C., et al. Discovery of the SARS-CoV-2 Papain-Like Protease Inhibitor MR1-114: From Structure-Based Design to In Vivo Antiviral Efficacy. Journal of Medicinal Chemistry, 2026. Link

[22] Tan, B., Zhang, X., Ansari, A., et al. Design of SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. bioRxiv, 2023. Link

[23] Lee, D.-Y., Sangket, U. ShinyVar: a web-based application for comparative Influenza variant analysis supporting structure-guided approaches to vaccine and antiviral drug design. PeerJ, 2026. Link

[24] Hausdorff, M., Delpal, A., Barelier, S., et al. Structure-guided optimization of adenosine mimetics as selective and potent inhibitors of coronavirus nsp14 N7-methyltransferases. European Journal of Medicinal Chemistry, 2023. Link

[25] Adediji, A., Sroithongmoon, A., Suroengrit, A., et al. Design, synthesis, and antiviral activity of fragmented-lapatinib aminoquinazoline analogs towards SARS-CoV-2 inhibition. European Journal of Medicinal Chemistry, 2025. Link

[26] Krishnathas, R., Mineev, K. S., Fourkiotis, N. K., et al. Structure-Based Rational Design of a Selective Hydrolase Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus-2 Nsp3 Macrodomain. ChemBioChem, 2025. Link

[27] Kitamura, N., Sacco, M., Ma, C., et al. An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity. bioRxiv, 2020. Link

[28] Akula, R., El Kilani, H., Metzen, A., et al. Structure-Based Optimization of Pyridone α-Ketoamides as Inhibitors of the SARS-CoV-2 Main Protease. Journal of Medicinal Chemistry, 2025. Link

[29] Chenthamarakshan, V., Hoffman, S. C., Owen, C., et al. Accelerating Inhibitor Discovery for Multiple SARS-CoV-2 Targets with a Single, Sequence-Guided Deep Generative Framework. arXiv, 2022. Link

[30] Nencka, R., Silhan, J., Klíma, M., et al. Coronaviral RNA-methyltransferases: function, structure and inhibition. Nucleic Acids Research, 2022. Link

[31] Westberg, M., Su, Y., Zou, X., et al. Design of SARS-CoV-2 protease inhibitors with improved affinity and reduced sensitivity to mutations. bioRxiv, 2023. Link

[32] Mik, V., Benz, L. S., Voller, J., et al. A patent review of Mpro protease inhibitors for the treatment of COVID-19 infections (2020 – present). Expert Opinion on Therapeutic Patents, 2025. Link

[33] van der Straat, R., Oerlemans, R., Cong, Y., et al. Ugi-Tetrazole-Derived α-Aminomethyl Scaffolds Reveal Unexpected Binding Modes in SARS-CoV-2 3CLpro. ACS Medicinal Chemistry Letters, 2026. Link

[34] Papini, C., Ullah, I., Ranjan, A., et al. Proof-of-concept studies with a computationally designed Mpro inhibitor as a synergistic combination regimen alternative to Paxlovid. Proceedings of the National Academy of Sciences, 2024. Link

[35] Tayeb-Fligelman, E., Bowler, J. T., Tai, C., et al. Low complexity domains of the nucleocapsid protein of SARS-CoV-2 form amyloid fibrils. Nature Communications, 2023. Link